EMERYVILLE, Calif., Oct. 24, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Monday, November 7, 2016 at 8:00 a.m. Mountain Time.
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, a modified-release version of an FDA-approved single-agent compound for the treatment of epilepsy. In addition, under a license agreement with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc., the company is eligible to receive royalties from Forest on sales of Namenda XR® and Namzaric™ beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
Contact: Martin Forrest VP Corporate Communications and Investor Relations 510-944-1112


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



